argenx - New CIDP & gMG data further underlines VYVGART (Hytrulo)'s value proposition
• ARGX shared additional results from the ADHERE (open-label) study and real-world data from gMG patients at the AAN Annual Meeting. • Data indicates rapid, deep, and clinically meaningful/sustained improvements in CIDP & with ability to reduce steroid burden (gMG). • We expect a positive outcome of the decision on regulatory approval for CDP by June 21 (85% LoA, +4% impact on TP) and currently project low double-digit million in sales this year. This might seem rather conservative (vs. gMG initial launch) but remember that reimbursement is expected to take around 2 quarters to get in place. Also, IVIg isArgenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.